# AcelRx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acelrx-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Redwood City, US
- Website: www.acelrx.com
- Latest round: Series C (Nov 13, 2009)
- Investors on record: 5

## About

AcelRx Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapies for medically supervised settings, particularly aimed at enhancing patient care and safety during procedures requiring anticoagulation.Founded in 2005, AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, US. The company specializes in developing therapies for patients who require anticoagulation during renal replacement therapy. Pamela Palmer is the founder. In February 2011, AcelRx raised USD 40 mn in a VENTURE DEBT funding round led by Hercules Capital, accumulating a total of USD 10 mn raised across 11 deals.AcelRx Pharmaceuticals is known for its core product, Niyad™ (nafamostat mesylate), designed as the first FDA-approved regional anticoagulant for extracorporeal circuits during renal replacement therapy. Additionally, the company collaborates with Laboratoire Aguettant to create prefilled syringe products like Fedsyra™ (ephedrine) and PFS-02 (phenylephrine), aimed at enhancing the administration of antihypotensive medications in acute care settings. AcelRx targets healthcare providers primarily in the United States, Japan, and South Korea, filling critical gaps in the market for anticoagulation therapies.In the most recent fiscal year 2023, AcelRx Pharmaceuticals reported revenue of USD 651,000. The company's EBITDA for 2024 was recorded at USD -15,131,000. AcelRx generates revenue through the sales of Niyad™, Fedsyra™, and PFS-02, along with a royalty agreement yielding 15% on net sales from DSUVIA, a previous product developed by the company.AcelRx Pharmaceuticals plans to leverage its recent funding of USD 40 mn raised in February 2011 to enhance product development and market penetration. The company is focused on launching new therapeutic solutions, expanding its product line, and entering additional markets in the US and Asia by 2024. AcelRx aims to address the increasing demand for effective anticoagulation therapies in medically supervised environments.

## Funding rounds

- Series C, Nov 13, 2009 — Alta Partners, Three Arch Partners, Pinnacle Ventures, Skyline Ventures, Kaiser Permanente Ventures

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series C
- Pinnacle Ventures (https://capitalatlas.ai/funds/pinnacle-ventures) — Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C